Volume-fraction-based determination for LLPS • Quantitative molecular assessment in phase-separated biomolecular systems


Processes and Methods (incl. Screening) : Life Sciences-HTS/HCS
Nucleic Acid-, Protein and Cell-related Technologies
Imaging and Microscopy

Ref.-No.: 1305-6270-IKF

This technology provides a label-free, volume-fraction-based method to quantify dense and dilute phase concentrations in liquid-liquid phase separation systems. It enables precise mapping of phase behavior from minimal sample volumes and is well suited for screening compounds, generating phase diagrams, and studying aberrant phase separation in disease-related biomolecular condensates.

Background

Liquid-liquid phase separation (LLPS) creates biomolecular condensates, which are key for cell function and signaling in development and disease. Measuring the concentrations within these dense phases is essential for understanding the formation, material properties, and dissolution of condensates. However, standard approaches need large sample volumes or rely on fluorescent tags, introducing artifacts and complicating quantification. A reliable, label-free quantification method would empower systematic studies in molecular biology and biomedicine, increase measurement precision, and broaden access to LLPS research.

Technology

Researchers from the Max-Planck-Institute of Molecular Cell Biology and Genetics in Dresden have developed a volume-fraction-based approach leveraging mass and volume conservation in closed systems, enabling simultaneous determination of dilute and condensed phase concentrations in LLPS for proteins or nucleic acids. The workflow is compatible with standard microscopy and microfluidic setups and works label-free or with minimal labeling.

Key features

Figure 1 Schematic of the binodal of a phase diagram with dilute branch cout and condensed branch cin concentrations connected via a tie line.

  • Quantitative binodal curves from minimal sample volumes
  • Label-free compatible, avoiding artifacts from fluorescence tags
  • 3-fold higher precision than conventional measurements for condensate composition
  • Scalable to in vitro, in vivo, and multi-well screening assays

 

 

Applications include rapid phase diagram mapping, screening for bioactive compounds modifying phase behavior, and diagnostic analyses for diseases involving aberrant phase separation.

Opportunity

We are seeking partners for licensing or collaboration to adapt and further develop this technology for broader clinical, pharmaceutical, and research applications.

Patent Information

The PCT application WO2023233040A1 was filed in 2025.

Publication

PDF Download

Contact

Senior Patent & License Manager

Dr. Ingrid Kapser-Fischer

Nutritionist, M.Sc.

+49 163 88 999 03
kapser-fischer@max-planck-innovation.de